Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Revolution Medicines (RVMD) over the last 7 years, with Dec 2024 value amounting to $44.6 million.

  • Revolution Medicines' Gains from Investment Securities rose 368.87% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.6 million, marking a year-over-year increase of 485.15%. This contributed to the annual value of $44.6 million for FY2024, which is 76.41% up from last year.
  • Latest data reveals that Revolution Medicines reported Gains from Investment Securities of $44.6 million as of FY2024, which was up 76.41% from $25.3 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Gains from Investment Securities peaked at $44.6 million during FY2024, and registered a low of $3.8 million during FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $25.3 million (2023), whereas its average is $24.6 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 5,325.00% in 2020, then tumbled by 89.28% in 2022.
  • Revolution Medicines' Gains from Investment Securities (Yearly) stood at $21.7 million in 2020, then soared by 63.30% to $35.4 million in 2021, then slumped by 89.28% to $3.8 million in 2022, then soared by 565.03% to $25.3 million in 2023, then surged by 76.41% to $44.6 million in 2024.